Table III.

Comparison between optimal LSS and reference design for estimating AUC^a_0-τ after IV MMF dosing

	Sampling time (hr)	Root mean sMSEb % (AUC0-τ)	Mean relative bias (rbias)% (AUC0-τ)	Pearson r	Percent of subjects with rbias% > 10%
Q 12 hr MMF dosing
Reference design	Pre-dose, 1, 2, 4, 6, 8, 10	17.62	9.19	0.97	1.7%
5-sample LSS	2, 2.5, 3, 5, 6	17.37	9.03	0.97	1.5%
4-sample LSS	2, 2.5, 3, 6	18.50	9.78	0.97	1.2%
3-sample LSS	2, 2.5, 5	20.56	10.8	0.97	3.2%
Q 8 hr MMF dosing
Reference design	Pre-dose, 1, 2, 4, 6, 8	18.37	10.0	0.97	1.7%
5-sample LSS	2, 2.5, 3, 4, 6	17.36	9.29	0.97	1.5%
4-sample LSS	2, 2.5, 3, 5	18.18	9.59	0.97	1.3%
3-sample LSS	2, 2.5, 5	20.30	11.0	0.98	2.5%

^aAUC_0-τ where τ is dosing frequency, so AUC_0-12hr for IV MMF dosed Q12 hrs and AUC_0-8hr for IV MMF dosed Q8hrs;

^bsMSE: scaled mean square error.